Mixture of MMP-2, MLC, and NOS Inhibitors Affects NO Metabolism and Protects Heart from Cardiac I/R Injury

Figure 1

Experimental protocol for ischemia/reperfusion (I/R) and aerobic control with or without administration of the mixture of doxycycline (MMP-2 inhibitor; 1.0 µM), L-NAME (NOS inhibitor; 2 µM), and ML-7 (inhibitor of MLC phosphorylation; 0.5 µM).